Drawing First Blood

Drawing First Blood

Two experts to debate controversial topics in hematology and health care.

Has ABIM Gone Too Far?

Thursday, January 26th, 2017
Recently, the American Board of Internal Medicine (ABIM) announced plans to implement new Maintenance of Certification (MOC) requirements, including requiring physicians to complete some...

To Test or Not to Test: Is Pharmacogenomic Testing for Warfarin Valuable?

Thursday, December 1st, 2016
Warfarin has been standard anticoagulation for more than 60 years, but the significant variability in both warfarin pharmacokinetics and pharmacodynamics makes achieving therapeutic drug...

Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A

Saturday, October 1st, 2016
Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For...

Is Fludarabine Dead in CLL?

Wednesday, March 2nd, 2016
A few short years ago, fludarabine was considered the gold standard of front-line treatment for chronic lymphocytic leukemia (CLL), providing better response rates than...

Rituximab or Splenectomy in Steroid-Resistant ITP Patients?

Monday, February 22nd, 2016
Corticosteroids are the standard initial treatment for adult patients with idiopathic thrombocytopenic purpura (ITP), while splenectomy is considered second-line treatment. Drugs like rituximab have...

Optimal Timing of Transplant in Myeloma

Wednesday, February 10th, 2016
New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront...

For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?

Saturday, October 17th, 2015
Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. While low-molecular-weight heparin (LMWH) anticoagulation therapy is a standard regimen...

To Transplant or Not To Transplant in First Remission?

Friday, June 26th, 2015
Most patients with newly diagnosed acute myeloid leukemia (AML) will achieve a first complete remission with standard induction chemotherapy. Durable remission or cure can only be attained, though, with further treatment...

Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines?

Thursday, December 25th, 2014
Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these...

Is There Still a Need for Radiation Therapy in Hodgkin Lymphoma?

Monday, November 10th, 2014
The standard treatment for certain types of Hodgkin lymphoma is combined modality therapy – consisting of chemotherapy followed by radiation therapy. Recently, there has...

Current Issue

March 2017, Volume 3, Issue 4

This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.